We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

POLX Polarean Imaging Plc

0.10 (2.56%)
16 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 2.56% 4.00 3.80 4.00 4.20 3.90 4.15 2,423,017 16:35:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 1.03M -13.91M -0.0644 -0.61 8.42M

Polarean Imaging PLC Block Listing Six Monthly Return

26/01/2024 7:00am

RNS Regulatory News

RNS Number : 9598A
Polarean Imaging PLC
26 January 2024

Polarean Imaging Plc

("Polarean" or the "Company")


Block Listing Six Monthly Return


Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:


Name of applicant:

Polarean Imaging Plc

Name of scheme:

Polarean Share Option Plan

Number and class of securities originally admitted:

8,000,000 ordinary shares of £0.00037 each

Date of admission:

29 July 2021

Period of return:


27 July 2023


26 January 2024

Balance of unallotted securities under scheme(s) from previous return:


Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):



Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):



Equals: Balance under scheme(s) not yet issued/allotted at end of period:


Total number of securities in issue at the end of the period


Name of contact:

Charles F. Osborne, Jr., Chief Financial Officer

Telephone number of contact:

+ 44 (0)20 7933 8780 or





Polarean Imaging plc /

Christopher von Jako, Chief Executive Officer

Via Walbrook PR

Charles Osborne, Chief Financial Officer



Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)

Nick Adams / Nick Harland (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or

Anna Dunphy /Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082


About Polarean (

The Company and its wholly-owned U.S. subsidiary, Polarean, Inc. are revenue-generating, medical imaging technology companies. The Company aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community which is desperately in need of new modern solutions to evaluate lung function. Polarean is dedicated to researching, developing, and commercialising these novel imaging solutions with their non-invasive and radiation-free functional MRI platform. The Company strives to address the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI contrast agent (XENOVIEW™) to be FDA-approved in the United States. The Company also commercialises the systems, software, and accessories to support fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

1 Year Polarean Imaging Chart

1 Year Polarean Imaging Chart

1 Month Polarean Imaging Chart

1 Month Polarean Imaging Chart

Your Recent History

Delayed Upgrade Clock